Boston Scientific Corporation $BSX Stock Acquired by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. boosted its holdings in Boston Scientific Corporation (NYSE:BSX) by 2,146.7% in the 3rd quarter, Holdings Channel reports. The firm owned 581,801 shares of the medical equipment provider’s stock after purchasing an additional 555,905 shares during the period. Jefferies Financial Group Inc.’s holdings in Boston Scientific were worth $25,396,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently bought and sold shares of BSX. First Command Advisory Services Inc. boosted its stake in shares of Boston Scientific by 145.1% during the third quarter. First Command Advisory Services Inc. now owns 3,841 shares of the medical equipment provider’s stock worth $168,000 after buying an additional 2,274 shares during the period. Silver Grove Financial Group Inc. grew its holdings in shares of Boston Scientific by 13.5% during the third quarter. Silver Grove Financial Group Inc. now owns 3,190 shares of the medical equipment provider’s stock worth $139,000 after buying an additional 379 shares during the last quarter. Turn8 Private Wealth Inc. grew its holdings in shares of Boston Scientific by 25.5% during the third quarter. Turn8 Private Wealth Inc. now owns 71,026 shares of the medical equipment provider’s stock worth $3,100,000 after buying an additional 14,421 shares during the last quarter. Knights of Columbus Asset Advisors LLC purchased a new position in shares of Boston Scientific during the third quarter worth about $4,634,000. Finally, AMG National Trust Bank acquired a new position in Boston Scientific in the 3rd quarter valued at about $1,497,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Trading Up 1.1%

NYSE BSX opened at $45.17 on Thursday. The company has a quick ratio of 0.81, a current ratio of 1.36 and a debt-to-equity ratio of 0.42. The stock has a market capitalization of $65.47 billion, a P/E ratio of 19.14, a P/E/G ratio of 1.32 and a beta of 0.60. Boston Scientific Corporation has a 52-week low of $39.57 and a 52-week high of $105.65. The firm has a 50-day moving average price of $44.13 and a 200 day moving average price of $54.99.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.73. Boston Scientific had a return on equity of 18.61% and a net margin of 16.62%. The company had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. During the same quarter in the previous year, the company earned $0.75 EPS. The firm’s revenue for the quarter was up 1.4% compared to the same quarter last year. Equities research analysts expect that Boston Scientific Corporation will post 3.17 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have commented on the company. Argus downgraded Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday, July 31st. Stifel Nicolaus cut their price target on Boston Scientific from $60.00 to $55.00 and set a “buy” rating for the company in a research note on Monday, October 26th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Boston Scientific in a report on Friday, October 2nd. Robert W. Baird increased their price target on Boston Scientific from $50.00 to $51.00 and gave the stock an “outperform” rating in a report on Thursday, October 29th. Finally, Deutsche Bank set a $48.00 price objective on shares of Boston Scientific and gave the company a “buy” rating in a research report on Thursday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $61.43.

Boston Scientific Company Profile

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.